Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
REVOLUTIONIZING DFU TREATMENT: ESCHAREX - A GAME-CHANGING SOLUTION (ESXDFU)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-12-01
End date: 2026-11-30
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

INTRODUCTION: MediWound develops wound care solutions, for chronic wounds and severe burns. The Company’s leading drug candidate under development and the subject of this EIC Accelerator project is EscharEx®, a groundbreaking bioactive therapy specifically targeting the debridement of Diabetic Foot Ulcers (DFUs) and other challenging chronic wounds. EscharEx is poised to revolutionize the standard of care (SOC) that for many patients is ineffective. EscharEx - A GAME-CHANGER IN CHRONIC WOUND CARE: EscharEx is a complex mixture of proteolytic enzymes, primarily bromelain, designed to selectively remove necrotic tissue and biofilm from chronic wounds. This process is highly efficient and does not harm viable tissue, providing an optimal wound bed for healing. Unlike traditional knife-based debridement, which can be traumatic and painful, EscharEx offers a non-surgical alternative that is swift, safe and effective. This aspect is especially critical for diabetic patients, often elderly and suffering from co-morbidities, who may find surgical options less suitable. The currently available non-surgical options are notoriously slow and ineffective, causing delays to the wound healing process, and resulting in significant incremental costs and poorer overall outcomes. CLINICAL PROGRESS AND VALIDATION: MediWound's confidence in EscharEx stems from the outcomes of three Phase 2 clinical studies. These studies demonstrated the therapy's rapid, safe, and effective debridement of DFUs and Venous Leg Ulcers (VLUs). Additionally, EscharEx shares the same active pharmaceutical ingredient as NexoBrid, MediWound's EMA and FDA-approved drug product for debridement of severe burn wounds. The consistency of active ingredients and similarity of indications between these two drugs provides additional support for the increased probability of success for EscharEx development and highlight the scientific rigor behind EscharEx's development.

Keywords: chronic wounds,severe burns,diabetic foot ulcer
Hybrid, Active Wheelchair (2)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 1000000.0
EU funding (EUR): 1000000.0
Participants: 1
Project status: SIGNED

The 1980s brought a significant step change in manual wheelchairs with the introduction of lightweight frames aimed at creating active independence. ‘Active independence’ describes the wheelchair user who leads an independent life and embraces an active lifestyle. These wheelchairs were significantly lighter and easier to use independently than their predecessors. However, since this step change nearly fifty years ago there has been virtually no advancement in the manual wheelchair. Meanwhile, prosthetic limbs have been transformed with smart technology and custom moulded, lightweight materials. This advancement in prosthetics has brought life changing independence and capabilities to amputees which in turn has created brand new, positive perceptions towards their disability. Phoenix Instinct is addressing the lack of innovation in the wheelchair sector that has seen wheelchair users seeking an active, independent life held back by tired technology. Founder Andrew Slorance a wheelchair user since SCI (spinal cord injury) at the age of fourteen is a proven entrepreneur with a track record of developing mobility products and bringing them to market. The company developed the first ever lightweight, hybrid wheelchair incorporating a revolutionary power assist function. Weighing only 7kg the Phoenix i wheelchair gives the user assisted propulsion and braking in a portable, stylish wheelchair that is life changing. The response from wheelchair users around the world to our new technology has been of great excitement and confirms the conventional wheelchair no longer meets the needs of modern life. Phoenix Instinct has developed an industry disrupting wheelchair that promises to advance mobility and change perceptions. To harness the opportunity, we are seeking EIC support to scale, streamline manufacturing and create compatibility for our technology to be installed on other brand wheelchairs allowing us to transform mobility on a global level.

Keywords: mobility independence equality
Distributed Control Infrastructure for Deeply Sovereign & Green Edge Clouds (DeepE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

The proposal “Distributed Control Infrastructure for Deeply Sovereign & Green Edge Clouds (DeepE)” is submitted by the real-cis GmbH, a start-up pursuing a unique and deep-tech business idea, which responses to sustainability and data sovereignty challenges in cloud computing. These sustainability challenges of the cloud are that huge amounts of heat is wasted by being blown out into open space, while the electricity for data centres is burdening the power grid and cloud server hardware is much too early renewed after a short life in service. The data sovereignty challenges are that providers have unnecessary privileged access to code and data being processed in the cloud. Ultra-high availability and low latency, cannot be delivered by cloud services out of data centres, and disparities between legal systems in Europe and abroad lead to insoluble data protection conflicts. DeepE responses to these challenges with a completely re-thought approach of a control infrastructure, which is designed for lowest carbon emissions and follows a security-first architecture. It yields substantial savings both in capital and operational expenditures, which enables the approach to disruptively capture market share. However, first the prototypically demonstrated but demanding technical solution for a distributed control infrastructure (TRL5) needs to be refined to be market-ready and proof-of-market has to be delivered in the proposed project. The experienced team already successfully built an ultra-high security cloud platform in the past and is led by a visionary, seasoned, yet energetic management team. A detailed business plan has been elaborated for this ambition, which results in funding requirements of approx. 30 M€, before positive cash flow. In two rounds 3 M€ have already been acquired. It is assumed that 40% of the total can be acquired from business angels. We apply for both, a grant of 2,5 M€ and 15 M€ in equity investment by the European Innovation Council.

Keywords: green edge cloud confidential computing green it lowest carbon responsible computing
Development of an AI-based thermal device for detecting signs of inflammation in arthritis patients (ArtiSee)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Lithuania
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Up to 1 of 4 adults are affected by arthritis, which is a leading cause of disability and a meaningful driver of economic costs. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common forms of arthritis. According to the World Health Organization, about 528 million people worldwide are living with osteoarthritis. Rheumatoid arthritis affects 18 million people worldwide, up to 1% of the global population. Arthritis and other rheumatic conditions are a leading cause of work disability among adults, they have a profound economic, personal, and societal impact. European countries have reported annual OA-related direct costs of €7.2 billion and indirect costs estimated to be as much as 4 times higher; OA responsible for the loss of 2 million years of healthy life annually in Europe. The total mean annual cost of RA across all European countries was estimated at about €45 billion. Arthritis, particularly RA, typically involves periods of disease activity (flares) and periods of reduced activity or remission. Progress can be unpredictable, and the disease evolve differently for each person. Early diagnosis and effective treatments, specifically treatment to suppress or control inflammation, can help reduce the damaging effects of these chronic disorders. Fortunately, with inflammation monitoring device ArtiSee arthritis management could be substantially improved. Timely interventions reduce pain, stiffness, and swelling, allowing individuals to perform daily activities with greater ease and slow down disease progression preventing joint damage, and improving overall quality of life for individuals with arthritis. Artisee is an innovative non-invasive at-home medical device for periodic evaluation of the temperature over the joints for signs of inflammation. Artisee’s contactless, compactness and ease of use attributes enhance the user autonomy, allowing them to operate the device with minimal to no assistance.

Keywords: rheumatoid arthritis,joints inflammation,remote monitoring,early diagnosis,telehealth,telemedicine
Nuada's novel optimised MOF reactors for CO2 capture (NUACO2)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Nuada (legal name: MOF Technologies Ltd) is a carbon capture technology provider based in Belfast (United Kingdom) that is dedicated to decarbonizing foundational and hard-to-abate industries with its next-generation point-source capture process. Leveraging over a decade of expertise in the development and application of metal-organic frameworks (MOFs), we have engineered an award-winning carbon capture process technology that is solving the energy, cost, and integrational challenges that are prohibiting the deployment of incumbent capture solutions. To advance scale-up and break into a new commercialisation phase, this project will focus on the development, validation and upscaling of novel optimised MOF reactor designs that will accelerate full-scale deployment opportunities, ensuring Nuada’s capture technology is market-ready by the end of the decade.

Keywords: carbon capture,climate change,energy efficiency
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeutics (NAD-ART)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Biotechnology and Biosystems E ngineering
Panel description: Biotechnology using all organisms , biotechnology for environment  and food applications, applied plant and animal sciences , bioengineering and synthetic biology , biomass and biofuels , biohazards
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 1499162.5
EU funding (EUR): 1499162.5
Participants: 2
Project status: SIGNED

Background: We discovered that NAD-capped RNAs can be covalently attached to specific target proteins by the phage T4 ADP-ribosyltransferase (ART) ModB, which we term RNAylation. Scientific problem: RNA therapy has almost limitless yet unexplored potential. Its translation into the clinics, however, requires optimal RNA delivery with high RNA stability, efficient cellular internalisation and precise target affinity. Hypothesis: Protein-RNA interactions are ubiquitous and central in biological control. I hypothesise that conjugating a NAD-capped nucleic acid to a protein catalysed by an ART generates a novel biomolecule – the RNAylated protein – with unique functionalities. The covalently linked protein or nucleic acid can trigger a directed intracellular delivery, where both, the protein and the nucleic acid, can become functionally active. This allows targeted modulation of translation or transcription, or editing. RNAylated proteins may provide a platform to engineer the cell and represent a starting point for the creation of next generation RNA therapeutics. Objectives: This project aims to establish RNAylated proteins as a fundamentally novel tool to regulate cellular processes. In objective 1, we will define the design principles for RNAylated proteins, allowing to control cellular processes. In objective 2, we will develop delivery strategies to transfer RNAylated proteins in specific cell types and allow for precise cellular localisation. In objective 3, we will combine the design and delivery principles for RNAylated proteins and apply them to target the tumour suppressor protein p53 by regulating translation, transcription or by editing. Impact: This project will develop RNAylated proteins as next generation RNA therapeutics and deepen our understanding of how a fundamental scientific discovery –the RNAylation of proteins, catalysed by the T4 ART ModB – can be translated into an application.

Keywords: rna modification,protein modification,nucleic acids,synthetic biology
Transformation of Eurasianism in the context of US Cold War Slavic Studies (COLD-WAR-EURASIA)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Czechia,United States
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-09-01
End date: 2029-08-31
Duration (months): 36.0
Total project cost (EUR): 419888.52
EU funding (EUR): 419888.52
Participants: 2
Project status: SIGNED

Eurasianism is an ideological and political movement that emerged in interwar Europe in the 1920s among Russian émigrés who left their country after the WWI and Bolshevik revolution. In the broader context of Russian intellectual thought, Eurasianism represents one of the most visible and important ideological movements that underwent a series of transformations during the 20th century and, especially since the early 1990s, has regularly resonated in Russian foreign policy and academic research. Until now, research on Eurasianism mostly focused on two main topics: interwar Eurasianism of the 1920s and 1930s and post-Soviet neo-Eurasianism of the 1990s. Although the research on both topics produced significant findings, the Cold War period remained without sought-after academic attention. In the current project, I aim to fill the blind spot in the study of Eurasianism by involving advanced digital analysis of unpublished archival documents from Prague, Saint Petersburg, and New York related to the development of Eurasianism in the US Cold War academia. Specifically, I will focus on Russian historian G. V. Vernadsky – one of the prominent members of the interwar Eurasianist movement who emigrated to the US in the late 1920s and pioneered Slavic studies at Yale. Throughout his outstanding academic career, Vernadsky remained in contact with numerous Russian emigrants, including Eurasianists N. S. Trubetzkoy and P. N. Savitsky and Soviet scholars, namely historian and ethnologist L. N. Gumilev, who became involved with Eurasianism in the late 1950s. In a broader context, the project will help to understand the transformation of Eurasianist concepts within the field of Russian, Eurasian, and Slavic Studies, and will comment on the roots of exploitation of Eurasianist concepts in contemporary Russian anti-Western propaganda. The main output of the project will be the first-ever monograph focused on the development of Eurasianism in the US Cold War Slavic Studies.

Keywords: cold war,eurasianism,slavic studies,us academia,russian emigration,historiography,digital humanities
The moleculaR mEchAnismS Of dNa methylatIon reprogrammiNg in Arabidopsis sexual lineaGe (REASONING)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Austria
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-04-01
End date: 2026-03-31
Duration (months): 24.0
Total project cost (EUR): 199440.96
EU funding (EUR): 199440.96
Participants: 1
Project status: SIGNED

In flowering plants, DNA methylation reprogramming occurs in meiocytes through RNA-directed DNA methylation pathway (RdDM) mediated by 24-nucleotide small interfering RNAs (siRNAs). My host lab discovered that these siRNAs are transcribed from transposable element (TE) in tapetal cells (tapetum) and transported to male meiocyte. In meiocytes, these siRNAs induce methylation at genes (MetGenes) with similar (but not identical) sequences, and thereby regulate MetGene expression and promote meiosis. The ability of siRNAs to target loci with reduced sequence homology is unique to meiocytes: in tapetum and somatic tissues, RdDM only targets TE with perfect sequence homology to siRNAs. The broad-targeting competence of tapetum siRNAs allows the targeting of MetGenes and fast-evolving TE in meiocytes, however, it is unclear how the broad targeting is achieved and comfined to the meiocytes. My preliminary work discovered several meiocyte-specific RdDM homologues, which I hypothesize to permit siRNA mismatch targeting. Furthermore, I found that RdDM mutants are hypersensitive to heat stress in meiocyte development, suggesting RdDM mediates heat stress response in meiocytes. Harnessing single-cell multi-omics, biochemistry and bio-imaging approaches, I aim to: 1) identity germline-specific RdDM homologues responsible for MetGenes targeting; 2) decipher how methylation of MetGenes are mediated by lncRNAs; and 3) uncover how the methylation reprogramming of MetGenes contributes to mediating male germline thermotolerance. My discoveries will elucidate essential siRNA regulatory mechanisms that mediate intergenerational heredity in plants and establish a novel epigenetic paradigm in how meiocytes perceive and respond to heat stress, essential knowledge for building crop resilience under climate change. This in-depth knowledge of cell- and site-specific RdDM pathway will also inform the generation of novel crop improvement tools by the engineering of methylation at gene families.

Keywords: sirna,dna methylation,mismatch,rddm,heat stress
Origins of Variability in Island Systems. Unraveling livestock diet and mobility across the Bronze-Iron Age transition (OVIS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-01-12
End date: 2028-01-11
Duration (months): 24.0
Total project cost (EUR): 276187.92
EU funding (EUR): 276187.92
Participants: 1
Project status: SIGNED

Between 1200-800 BCE, the socio-economic and political system that characterised the Bronze Age “collapsed” on a large scale. The island communities in the Western Mediterranean experienced nearly parallel social transformations during this time period, such as increased social hierarchisation and architectural shifts aimed to controlling natural resources. The OVIS project will focus on study animal diet and mobility with the aim to reconstruct the historical role of such economic and landscapes practices in the Bronze-Iron Age transition. Crucially, the project will also provide essential data on climate events and their influence on this transformative period. To achieve these objectives, OVIS will employ cutting-edge zooarchaeological techniques, including carbon and oxygen isotopes and dental microwear analysis on sheep teeth, across a macro-regional scale (Sardinia, Mallorca and Menorca) and diachronically over 1,600 years. This will constitute the largest zooarchaeological study using high-resolution methods in these contexts. The project’s extensive geographical and temporal perspectives will help resolve existing uncertainities about the causes and consequences of the rapid transition from the Bronze Age to the Iron Age, both locally and across the Mediterranean. Finally, OVIS will generate long-term scientific benefits by delivering paleoclimatic data and examining how island populations adapted to potential water shortages and climatic change. This work will offer vital insights into the challenges of the near future.

Keywords: zooarchaeology,island archaeology,dental microwear,oxygen isotopes,carbon isotopes,climate change,sardinia,balearic islands,mediterranean